Development of laquinimod for relapsing-remitting multiple sclerosis

Future Neurology

Volumn 3, Issue 6, 2008, Pages 641-648

  Jeffery, Douglas R ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

Clinical trials; Experimental allergic encephalitis; Laquinimod; Mechanism of action; Multiple sclerosis

Indexed keywords

ALEMTUZUMAB; AMIODARONE; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CALCIUM CHANNEL BLOCKING AGENT; CLADRIBINE; DACLIZUMAB; ERYTHROMYCIN; FINGOLIMOD; FLUCONAZOLE; FLUOXETINE; FLUVOXAMINE; FUMARIC ACID DIMETHYL ESTER; GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE; INTERLEUKIN 12; LAQUINIMOD; MITOXANTRONE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NATALIZUMAB; OFLOXACIN; PLACEBO; RITUXIMAB; ROQUINIMEX; SERTRALINE; TERIFLUNOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ABDOMINAL PAIN; ALLERGIC ENCEPHALITIS; ALLERGIC ENCEPHALOMYELITIS; ALLERGIC NEUROPATHY; AMENORRHEA; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; BLOOD CLOTTING FACTOR 5 DEFICIENCY; BUDD CHIARI SYNDROME; CARDIOTOXICITY; CELLULAR IMMUNITY; CHEST TIGHTNESS; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; EOSINOPHILIA; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HUMAN; INFECTION; INFERTILITY; INFLAMMATION; INJECTION SITE REACTION; LEUKEMIA; LEUKOPENIA; LIVER TOXICITY; LIVER VEIN THROMBOSIS; MAXIMUM PLASMA CONCENTRATION; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PERICARDITIS; PHARYNGITIS; PLEURISY; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SIDE EFFECT; TH1 CELL; TH2 CELL; VOMITING;

EID: 67149107174     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/14796708.3.6.641     Document Type: Article

References (26)

1. Weinshenker BG, Bass B, Rice GP et al.: The natural history of multiple sclerosis: a geographically based study. I. Clinic course and disability. Brain 112, 133-146 (1989).
2. Lublin FD, Reingold SC: Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 46, 907-911 (1996).
3. Anderson DW, Ellenberg JH, Leventhal CM et al.: Revised estimate of the prevalence of multiple sclerosis in the United States. Ann. Neural. 31, 333-336 (1992).
4. Rovaris M, Confacreux C, Furlan R, Kappos L, Comi G, Filippi M: Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet 5, 343-354 (2006).
5. Jeffery DR: Early interventions with immunodulatory agents in the treatment of multiple sclerosis. J. Neurol Sci. 197, 1-8 (2002).
6. Jeffery DR, Heindon R: Review of mitoxantrone in the treatment of multiple sclerosis. Neurology 63 (6), S19-S24 (2004).
7. Polman CH, O'Connor PW, Havrdova E et al.: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354, 899-910 (2006).
8. Yoursy TA, Habi M, Major E et al.: Evaluation of patients treated with nataluzimab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 354, 924-933 (2006).
9. Bozic C, Belcher G, Kooijmans-Coutinho M et al.: Natalizumab utilization and safety in patients with relapsing multiple sclerosis: updated results from TOUCH and, TYGRIS. Neurology 70(Suppl. 1) A104 (2008).
10. Noseworthy JH, Wolinsky JS, Lublin FD et al.: Linomide in relapsing and secondary progressive MS: part 1: trial design and clinical results. Neurology 54(9), 1726-1733 (2000).
11. Jonsson S. Andersson G, Fex T et al.: Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3 quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J. Med. Chem. 47, 2075-2088 (2004).
12. Zou L, Abbas N, Volkman I et al.: Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into peripheral nervous tissue. Neuropharmacology 42, 731-739 (2002).
13. DeAngelis T, Lublin F: Multiple sclerosis: new treatment trials and emerging therapeutic targets. Curr. Opin. Neurol. 21, 261-271 (2008).
14. Tuvesson H, Hallin I, Ellman M, Sparre B, Gunnarsson PO, Seidegard J: In vitro metabolism and in vivo pharmacokinetics in quinoline 3-carboxamide derivatives in various species. Xenobiotica 35(3), 295-304 (2005).
15. Tuvesson H, Hallin I, Persson R, Sparre B, Gunnarsson PO, Seidegard J: Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator. Drug Metab. Dispos. 33, 866-872 (2005).
16. Fox EJ: Immunopathology of multiple sclerosis. Neurology 63 (Suppl. 6), S3-S7 (2004).
17. Hafler DA: Multiple sclerosis. J. Clin. Invest. 113(6), 788-794 (2004).
18. Brunmark C, Runstrom A, Ohlsson L et al.: The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 130, 163-172 (2002).
19. Yang J-S, Xu LY, Xiao BG, Hedlund G, Link H: Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-β in Lewis rats. J. Neuroimmunol. 156, 3-9 (2004).
20. Runstrom A, Leanderson T, Ohlsson L, Axelsson B: Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-β k.o. and wild type mice. J. Neuroimmunol. 173, 69-78 (2006).
21. Blanchette F, Neuhaus O: Glatiramer acetetate: evidence for a dual mechanism of action. J. Neurol. 255(Suppl. 1), 26-36 (2008).
22. Achiron A, Or-Bach R, Barsilay S, Gurevich M: Laquinimod induced downregulation of MHC class II gene expression in cultured peripheral blood cells of untreated patients with multiple sclerosis. Neurology 70(Suppl.), A376 (2008).
23. Polman C, Barkof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T: Laquinimod in Relapsing MS Study Group. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 64, 987-991 (2005).
24. Comi, G, Pulizzi A, Rovaris M et al.: Effect of laquinimod on MRI-monitored disease activity in relapsing - remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled Phase IIb study. Lancet 317, 2085-2092 (2008).
25. Comi G, Abramsky O, Arbizu T et al.: For the LAQ/5062 Clinical Advisory Board and Study Group. J. Neurol. 255(3), 0193 (2008).
26. Sandberg-Wollheim M, Nederman T, Linde A: 48-week open safety study with a high dose oral laquinimod in MS patients. Mult. Scler. 11, P587 (2005).